[1]李玉平,王伦善.血清TSH,TPOAb和TGAb水平在良恶性甲状腺结节中的鉴别诊断价值[J].现代检验医学杂志,2019,34(05):93-97.[doi:10.3969/j.issn.1671-7414.2019.05.023]
　LI Yu-ping,WANG Lun-shan.Diagnostic Value of Thyroid Autoantibodies and TSH in Thyroid Nodules[J].Journal of Modern Laboratory Medicine,2019,34(05):93-97.[doi:10.3969/j.issn.1671-7414.2019.05.023]
点击复制

血清TSH,TPOAb和TGAb水平在良恶性甲状腺结节中的鉴别诊断价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
93-97
栏目:
论著
出版日期:
2019-10-29

文章信息/Info

Title:
Diagnostic Value of Thyroid Autoantibodies and TSH in Thyroid Nodules
文章编号:
1671-7414(2019)05-093-05
作者:
李玉平; 王伦善
(中国人民解放军联勤保障部队第九○一医院检验科,合肥 230031)
Author(s):
LI Yu-ping; WANG Lun-shan
(Department of Clinical Laboratory, the 901th Hospital of the Joint Logistics Support Force of PLA,Hefei 230031,China)
关键词:
甲状腺结节;  乳头状甲状腺癌;  促甲状腺激素;  甲状腺过氧化物酶抗体;  甲状腺球蛋白抗体
分类号:
R736.1; R730.43
DOI:
10.3969/j.issn.1671-7414.2019.05.023
文献标志码:
A
摘要:
目的 研究促甲状腺激素(thyroid stimulating horomone,TSH)和甲状腺自身抗体(TPOAb,TGAb)在良恶性甲状腺结节中的鉴别诊断价值。方法 采用回顾性调查研究方法,收集中国人民解放军联勤保障部队第九○一医院2013年3月～2018年9月期间因甲状腺结节行手术治疗且经病理证实的500例临床资料,其中分化型甲状腺癌(differentiated thyroid carcinoma,DTC)152例,甲状腺腺瘤(thyroid adenoma,TA)232例,结节性甲状腺肿(nodular goiter,NG)116例,并对检测结果进行统计分析。结果 DTC组的TSH,TPOAb和TGAb水平显著高于TA组和NG组,经单因素方差分析,差异有统计学意义(F=4.120,4.636,6.638; P=0.016,0.01,0.001)。TSH在DTC组与良性甲状腺疾病的阳性率无差别,TPOAb在DTC组的阳性率为30.2%,而在TA组和NG组的阳性率分别为12.5%和13.7%,差异有统计学意义(χ2=21.43,P<0.01)。DTC组的TGAb阳性率为26.9%,而TA和NG组的阳性率分别为15.5%和12.0%,差异有统计学意义(χ2=11.91,P=0.002)。转移性DTC和未转移性DTC组的TSH,TPOAb和TGAb,经t检验统计分析,差异无统计学意义(t=1.976,1.974,1.973; P=0.572,0.574,0.577)。TPOAb和TGAb在鉴别DTC和TA的曲线下面积分别是0.612和0.610。TPOAb和TGAb在鉴别DTC和NG的曲线下面积分别是0.577和0.620。TGAb在最佳临界点诊断DTC的敏感度为73.7%,特异度为52.6%。结论 TSH浓度和甲状腺自身抗体水平升高与DTC的发病有一定的相关关系,TGAb在甲状腺癌和甲状腺良性结节的鉴别诊断中具有一定价值。
Abstract:
Objective To investigate the diagnostic value of thyroid stimulating hormone(TSH)and thyroid autoantibodies(TPOAb,TGAb)in benign and malignantthyroid nodules.Methods A retrospective investigation method was used to collect the pathological and clinical data of 500 cases of thyroid nodules treated with surgery and pathological confirmation from March 2013to September 2018,including 152 cases of papillary thyroid carcinoma,232 casesof thyroid adenomas,and 116 cases of nodular goiter.Results The levels of TSH,TPOAb and TGAb in the thyroid cancer group were significantly higher than those of the thyroid adenomas group and the nodular goiter group(F=4.120,4.636 and 6.638; P=0.016,0.01,0.001).The positiverate of TSH in thyroid cancer and benign thyroid disease groups was not significantly different,but the positive rate of TPOAb and TGAb was significantly higher than that of two other groups.The positive rate of TPOAb in thyroid papillary carcinoma was 30.2%,and the positive rates of thyroid adenomas group and thethyroid nodular goiter group were 12.5% and 13.7%(χ2=21.43,P<0.01)respectively.The positive rate of TGAb in papillary thyroid carcinoma was 26.9%,while the positive rate in thyroid adenomas and nodular goiter was 15.5%and 12.0%(χ2=11.91,P=0.002)respectively.TSH,TPOAb and TGAb of metastatic DTC and non-DTC groups were statistically analyzed by t test,the difference was not statistically significant(t=1.976,1.974 and 1.973,P=0.572,0.546 and 0.577).The ROC curve analysis showed that the areas under the curve of the papillary carcinoma and thyroid adenomas were 0.612 and 0.610,respectively.To diagnose papillary carcinoma and nodular goiter,the areasunder the curve of TPOAb and TGAb were 0.577 and 0.620,respectively.The sensitivity of TGAb to diagnose thyroid cancer at the optimal critical point was 73.7%,and the specificity was 52.6%.Conclusion The increase of TSH concentration and thyroid autoantibodies had a little correlation with the incidence of papillary thyroid cancer.TGAb has preliminary diagnostic value for thyroid cancer.

参考文献/References:

[1] CABANILLAS M E,MCFADDEN D G,DURANTE C.Thyroid cancer[J].Lancet,2016,388(10061):2783-2795. [2] 陈万青,李贺,孙可欣,等.2014年中国恶性肿瘤发病和死亡分析[J].中华肿瘤杂志,2018,40(1):5-13. CHEN Wanqing,LI He,SUN Kexin,et al.Report of cancer incidence and mortality in China,2014[J].Chin J Oncol,2018,40(1):5-13. [3] SMITH-BINDMAN R,LEBDA P,FELDSTEIN V A,et al.Risk of thyroid cancer based on thyroid ultrasound imaging characteristics:results of a population-based study[J].JAMA Intern Med,2013,173(19):1788-1796. [4] HAUGEN B R,ALEXANDER E K,BIBLE K C,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133. [5] 闫慧娴,谷伟军,杨国庆,等.血清促甲状腺激素与甲状腺乳头状微小癌相关性研究[J].中华内分泌代谢杂志,2014,30(8):669-672. YAN Huixian,GU Weijun,YANG Guoqing,et al.Association of serum thyrotropin level with papillary thyroid microcarcinoma[J].Chin J Endocrinol Metab,2014,30(8):669-672. [6] LIU Xiaoyun,ZHU Lijun,CUI Dai,et al.Coexistence of histologically confirmed Hashimoto's thyroiditis with different stages of papillary thyroid carcinoma in a consecutive Chinese cohort[J].Int J Endocrinol,2014,2014(14):769294. [7] GABALEC F,SRBOVA L,NOVA M,et al.Impact of Hashimoto's thyroiditis,TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence[J].Endokrynol Pol,2016,67(1):48-53. [8] SELEK A,CETINARSLAN B,TARKUN I,et al.Thyroid autoimmunity:is reallyassociated with papillary thyroid carcinoma[J].Eur Arch Otorhinolaryngol,2017,274(3):1677-1681. [9] 王禹,李秀娥,王双云.2型糖尿病患者甲状腺功能的调查分析[J].现代检验医学杂志,2012,27(2):132-133,136. WANG Yu,LI Xiue,WANG Shuangyun.Thyroid function investigation and analysis of patients with type 2 diabetes[J].J Mod Lab Med,2012,27(2):132-133,136. [10] 赵勇,陈波,黄迅,等.促甲状腺激素及甲状腺自身抗体水平与甲状腺结节良恶性的关系[J].中国现代医学杂志,2012,22(8):41-44. ZHAO Yong,CHEN Bo,HUANG Xun,et al.Relationship between the serum level of thyrotropin,auto-antibodies and the nature of thyroid nodules[J].ChinaJournal of Modern Medicine,2012,22(8):41-44. [11] KRáTKY J,JEZKOVá J,KOSáK M,et al.Positive antithyroid antibodiesand nonsuppressed TSH are associated with thyroid cancer:a retrospective cross-sectional study[J].Int J Endocrinol,2018,2018(6):9793850. [12] BOELAERT K,HORACEK J,HOLDER R L,et al.Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration[J].J Clin Endocrinol Metab,2006,91(11):4295-4301. [13] FIORE E,RAGO T,PROVENZALE M A,et al.Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease:thyroid autonomy may play a protective role[J].Endocr Relat Cancer,2009,16(4):1251-1260. [14] PARK J H,LEE Y M,LEE Y H,et al.The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma[J].J Surg Oncol,2018,118(3):390-396. [15] XIE Xiaochen,SHI Xiaoguang,GUAN Haixia,et al.P21-activated kinase 4involves TSH induced papillary thyroid cancer cell proliferation[J].Oncotarget,2017,8(15):24882-24891. [16] AZIZI G,KELLER J M,LEWIS M,et al.Association of hashimoto's thyroiditis with thyroid cancer[J].Endocr Relat Cancer,2014,21(6):845-852. [17] QIN Jing,YU Zhenqian,GUAN Haixia,et al.High thyroglobulin antibodylevels increase the risk of differentiated thyroid carcinoma[J].Dis Markers,2015,2015(17):648670. [18] VEIT F,GRAF D,MOMBRERGER S,et al.Papillary thyroid cancer and coexisting autoimmune thyroiditis[J].Horm Metab Res,2017,49(11):869-872. [19] RAKIB S A,SHARIF S B,NAHAR A,et al.Prediction of thyroid malignancies by thyroid auto antibodies[J].Mymensingh Med J,2018,27(3):585-595. [20] SHEN Chentian,ZHANG Xinyun,QIU Zhongling,et al.Thyroid autoimmuneantibodies in patients with papillary thyroid carcinoma:a double-edged sword[J].Endocrine,2017,58(1):176-183.

备注/Memo

备注/Memo:
作者简介:李玉平(1970-),女,本科,主管技师,从事临床检验工作,E-mail:lyp105jyk@163.com。 通讯作者:王伦善(1969-),男,硕士,副主任技师,从事肿瘤早期诊断研究,E-mail:wanglunshan@163.com。
更新日期/Last Update: 2019-10-20